Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Nutrition Adequacy Therapeutic Enhancement in the Critically Ill: A Randomized Double-Blind, Placebo-Controlled Trial of the Motilin Receptor Agonist Camicinal (GSK962040): The NUTRIATE Study.

Deane AM, Lamontagne F, Dukes GE, Neil D, Vasist L, Barton ME, Hacquoil K, Ou X, Richards D, Stelfox HT, Mehta S, Day AG, Chapman MJ, Heyland DK.

JPEN J Parenter Enteral Nutr. 2018 Jul;42(5):949-959. doi: 10.1002/jpen.1038. Epub 2017 Dec 28.

PMID:
29957868
2.

A randomized, double-blind, placebo-controlled trial of camicinal in Parkinson's disease.

Marrinan SL, Otiker T, Vasist LS, Gibson RA, Sarai BK, Barton ME, Richards DB, Hellström PM, Nyholm D, Dukes GE, Burn DJ.

Mov Disord. 2018 Feb;33(2):329-332. doi: 10.1002/mds.27259. Epub 2017 Dec 26.

3.

Manometric evaluation of the motilin receptor agonist camicinal (GSK962040) in humans.

Deloose E, Depoortere I, de Hoon J, Van Hecken A, Dewit OE, Vasist Johnson LS, Barton ME, Dukes GE, Tack J.

Neurogastroenterol Motil. 2018 Jan;30(1). doi: 10.1111/nmo.13173. Epub 2017 Aug 6.

PMID:
28782145
4.

Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study.

Hegade VS, Kendrick SF, Dobbins RL, Miller SR, Thompson D, Richards D, Storey J, Dukes GE, Corrigan M, Oude Elferink RP, Beuers U, Hirschfield GM, Jones DE.

Lancet. 2017 Mar 18;389(10074):1114-1123. doi: 10.1016/S0140-6736(17)30319-7. Epub 2017 Feb 8.

PMID:
28187915
5.

The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial.

Chapman MJ, Deane AM, O'Connor SL, Nguyen NQ, Fraser RJ, Richards DB, Hacquoil KE, Vasist Johnson LS, Barton ME, Dukes GE.

Crit Care. 2016 Aug 1;20(1):232. doi: 10.1186/s13054-016-1420-4.

6.

The pharmacodynamics, safety and pharmacokinetics of single doses of the motilin agonist, camicinal, in type 1 diabetes mellitus with slow gastric emptying.

Hellström PM, Tack J, Johnson LV, Hacquoil K, Barton ME, Richards DB, Alpers DH, Sanger GJ, Dukes GE.

Br J Pharmacol. 2016 Jun;173(11):1768-77. doi: 10.1111/bph.13475. Epub 2016 Apr 13.

7.

The effects of camicinal, a novel motilin agonist, on gastro-esophageal function in healthy humans-a randomized placebo controlled trial.

Hobson R, Farmer AD, Dewit OE, O'Donnell M, Hacquoil K, Robertson D, Barton ME, Dukes GE.

Neurogastroenterol Motil. 2015 Nov;27(11):1629-37. doi: 10.1111/nmo.12663. Epub 2015 Sep 8.

PMID:
26348542
8.

Caecal pH is a biomarker of excessive colonic fermentation.

Farmer AD, Mohammed SD, Dukes GE, Scott SM, Hobson AR.

World J Gastroenterol. 2014 May 7;20(17):5000-7. doi: 10.3748/wjg.v20.i17.5000.

9.

Drugs acting at 5-HT4 , D2 , motilin, and ghrelin receptors differ markedly in how they affect neuromuscular functions in human isolated stomach.

Broad J, Góralczyk A, Mannur K, Dukes GE, Sanger GJ.

Neurogastroenterol Motil. 2014 Jun;26(6):851-61. doi: 10.1111/nmo.12338. Epub 2014 Apr 20.

PMID:
24750304
10.

Impaired emotional learning and involvement of the corticotropin-releasing factor signaling system in patients with irritable bowel syndrome.

Labus JS, Hubbard CS, Bueller J, Ebrat B, Tillisch K, Chen M, Stains J, Dukes GE, Kelleher DL, Naliboff BD, Fanselow M, Mayer EA.

Gastroenterology. 2013 Dec;145(6):1253-61.e1-3. doi: 10.1053/j.gastro.2013.08.016. Epub 2013 Aug 14. Review.

11.

Anti-emetic and emetic effects of erythromycin in Suncus murinus: role of vagal nerve activation, gastric motility stimulation and motilin receptors.

Javid FA, Bulmer DC, Broad J, Aziz Q, Dukes GE, Sanger GJ.

Eur J Pharmacol. 2013 Jan 15;699(1-3):48-54. doi: 10.1016/j.ejphar.2012.11.035. Epub 2012 Nov 28.

PMID:
23201066
12.

Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFα.

Swan C, Duroudier NP, Campbell E, Zaitoun A, Hastings M, Dukes GE, Cox J, Kelly FM, Wilde J, Lennon MG, Neal KR, Whorwell PJ, Hall IP, Spiller RC.

Gut. 2013 Jul;62(7):985-94. doi: 10.1136/gutjnl-2011-301213. Epub 2012 Jun 8.

PMID:
22684480
13.

Regional- and agonist-dependent facilitation of human neurogastrointestinal functions by motilin receptor agonists.

Broad J, Mukherjee S, Samadi M, Martin JE, Dukes GE, Sanger GJ.

Br J Pharmacol. 2012 Oct;167(4):763-74. doi: 10.1111/j.1476-5381.2012.02009.x.

14.

GSK962040: a small molecule motilin receptor agonist which increases gastrointestinal motility in conscious dogs.

Leming S, Broad J, Cozens SJ, Otterson M, Winchester W, Lee K, Dukes GE, Sanger GJ.

Neurogastroenterol Motil. 2011 Oct;23(10):958-e410. doi: 10.1111/j.1365-2982.2011.01770.x. Epub 2011 Sep 5.

PMID:
21895874
15.

Corticotropin-releasing factor receptor 1 antagonist alters regional activation and effective connectivity in an emotional-arousal circuit during expectation of abdominal pain.

Hubbard CS, Labus JS, Bueller J, Stains J, Suyenobu B, Dukes GE, Kelleher DL, Tillisch K, Naliboff BD, Mayer EA.

J Neurosci. 2011 Aug 31;31(35):12491-500. doi: 10.1523/JNEUROSCI.1860-11.2011.

16.

Distinct neurophysiological profiles in irritable bowel syndrome.

Arebi N, Bullas DC, Dukes GE, Gurmany S, Hicks KJ, Kamm MA, Hobson AR.

Am J Physiol Gastrointest Liver Physiol. 2011 Jun;300(6):G1086-93. doi: 10.1152/ajpgi.00553.2010. Epub 2011 Feb 24.

17.

The Patient Health Questionnaire 12 Somatic Symptom scale as a predictor of symptom severity and consulting behaviour in patients with irritable bowel syndrome and symptomatic diverticular disease.

Spiller RC, Humes DJ, Campbell E, Hastings M, Neal KR, Dukes GE, Whorwell PJ.

Aliment Pharmacol Ther. 2010 Sep;32(6):811-20. doi: 10.1111/j.1365-2036.2010.04402.x.

18.

The effects of a short course of antibiotics on alvimopan and metabolite pharmacokinetics.

Schmith VD, Johnson BM, Vasist LS, Kelleher DL, Hewens DA, Young MA, Ameen V, Dukes GE.

J Clin Pharmacol. 2010 Mar;50(3):338-49. doi: 10.1177/0091270009347474. Epub 2009 Oct 1.

PMID:
19797535
19.

Irritable bowel syndrome: more than abdominal pain and bowel habit abnormalities.

Bond B, Quinlan J, Dukes GE, Mearin F, Clouse RE, Alpers DH.

Clin Gastroenterol Hepatol. 2009 Jan;7(1):73-9. doi: 10.1016/j.cgh.2008.08.011. Epub 2008 Aug 19.

20.

Dose-response effect of a beta3-adrenergic receptor agonist, solabegron, on gastrointestinal transit, bowel function, and somatostatin levels in health.

Grudell AB, Camilleri M, Jensen KL, Foxx-Orenstein AE, Burton DD, Ryks MD, Baxter KL, Cox DS, Dukes GE, Kelleher DL, Zinsmeister AR.

Am J Physiol Gastrointest Liver Physiol. 2008 May;294(5):G1114-9. doi: 10.1152/ajpgi.00051.2008. Epub 2008 Mar 27.

21.

Effect of the NK(3) receptor antagonist, talnetant, on rectal sensory function and compliance in healthy humans.

Houghton LA, Cremonini F, Camilleri M, Busciglio I, Fell C, Cox V, Alpers DH, Dewit OE, Dukes GE, Gray E, Lea R, Zinsmeister AR, Whorwell PJ.

Neurogastroenterol Motil. 2007 Sep;19(9):732-43.

PMID:
17727393
22.

A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.

Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA.

Am J Gastroenterol. 2005 Jan;100(1):115-23.

PMID:
15654790
23.

Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.

Chey WD, Chey WY, Heath AT, Dukes GE, Carter EG, Northcutt A, Ameen VZ.

Am J Gastroenterol. 2004 Nov;99(11):2195-203.

PMID:
15555002
24.

Association between a functional polymorphism in the serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in women.

Yeo A, Boyd P, Lumsden S, Saunders T, Handley A, Stubbins M, Knaggs A, Asquith S, Taylor I, Bahari B, Crocker N, Rallan R, Varsani S, Montgomery D, Alpers DH, Dukes GE, Purvis I, Hicks GA.

Gut. 2004 Oct;53(10):1452-8.

25.

A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.

Camilleri M, Chey WY, Mayer EA, Northcutt AR, Heath A, Dukes GE, McSorley D, Mangel AM.

Arch Intern Med. 2001 Jul 23;161(14):1733-40.

PMID:
11485506
26.

Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients.

Wolfe SG, Chey WY, Washington MK, Harding J, Heath AT, McSorley DJ, Dukes GE, Hunt CM.

Am J Gastroenterol. 2001 Mar;96(3):803-11.

PMID:
11280555
27.

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.

Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW.

Lancet. 2000 Mar 25;355(9209):1035-40.

PMID:
10744088
28.

Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist.

Camilleri M, Mayer EA, Drossman DA, Heath A, Dukes GE, McSorley D, Kong S, Mangel AW, Northcutt AR.

Aliment Pharmacol Ther. 1999 Sep;13(9):1149-59.

29.

Use of a novel electronic data collection system in multicenter studies of irritable bowel syndrome.

Harding JP, Hamm LR, Ehsanullah RS, Heath AT, Sorrells SC, Haw J, Dukes GE, Wolfe SG, Mangel AW, Northcutt AR.

Aliment Pharmacol Ther. 1997 Dec;11(6):1073-6.

30.

Adequate relief as an endpoint in clinical trials in irritable bowel syndrome.

Mangel AW, Hahn BA, Heath AT, Northcutt AR, Kong S, Dukes GE, McSorley D.

J Int Med Res. 1998 Mar-Apr;26(2):76-81.

PMID:
9602985
31.

Issues and trends in clinical pharmacy practice, research, and education: an introduction.

Dukes GE.

Pharmacotherapy. 1997 Sep-Oct;17(5):1062. No abstract available.

PMID:
9324202
32.

Pharmacokinetics of amiloride after inhalation and oral administration in adolescents and adults with cystic fibrosis.

Jones KM, Liao E, Hohneker K, Turpin S, Henry MM, Selinger K, Hsyu PH, Boucher RC, Knowles MR, Dukes GE.

Pharmacotherapy. 1997 Mar-Apr;17(2):263-70.

PMID:
9085317
33.

Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis.

Knupp CA, Hak LJ, Coakley DF, Falk RJ, Wagner BE, Raasch RH, van der Horst CM, Kaul S, Barbhaiya RH, Dukes GE.

Clin Pharmacol Ther. 1996 Nov;60(5):535-42.

PMID:
8941026
34.

Pharmacokinetics of ondansetron in patients with hepatic insufficiency.

Figg WD, Dukes GE, Pritchard JF, Hermann DJ, Lesesne HR, Carson SW, Songer SS, Powell JR, Hak LJ.

J Clin Pharmacol. 1996 Mar;36(3):206-15.

PMID:
8690814
35.

Comparison of quantitative methods to assess hepatic function: Pugh's classification, indocyanine green, antipyrine, and dextromethorphan.

Figg WD, Dukes GE, Lesesne HR, Carson SW, Songer SS, Pritchard JF, Hermann DJ, Powell JR, Hak LJ.

Pharmacotherapy. 1995 Nov-Dec;15(6):693-700.

PMID:
8602375
36.

Sumatriptan absorption from different regions of the human gastrointestinal tract.

Warner PE, Brouwer KL, Hussey EK, Dukes GE, Heizer WD, Donn KH, Davis IM, Powell JR.

Pharm Res. 1995 Jan;12(1):138-43.

PMID:
7724476
37.

A dose-response study of orally administered torsemide in patients with ascites due to cirrhosis.

Applefeld JJ, Kasmer RJ, Hak LJ, Dukes GE, Wermeling DP, McClain CJ.

Aliment Pharmacol Ther. 1994 Aug;8(4):397-402.

PMID:
7986964
38.

Venous irritation related to intravenous administration of phenytoin versus fosphenytoin.

Jamerson BD, Dukes GE, Brouwer KL, Donn KH, Messenheimer JA, Powell JR.

Pharmacotherapy. 1994 Jan-Feb;14(1):47-52.

PMID:
8159601
39.

Inline filtration of ondansetron hydrochloride during simulated i.v. administration.

Liao E, Fox JL, Dukes GE.

Am J Hosp Pharm. 1993 May;50(5):906, 909. No abstract available.

PMID:
8506862
40.

Ondansetron: a novel antiemetic agent.

Figg WD, Graham CL, Hak LJ, Dukes GE.

South Med J. 1993 May;86(5):497-502. Review.

PMID:
8488393
41.

Pharmacotherapy specialty certification examination. IV. 1992 results and process modifications, including recertification. The 1992 Specialty Council on Pharmacotherapy, Board of Pharmaceutical Specialties.

Zarowitz BJ, Vlasses PH, Dukes GE, Gal P, Miller WA, Porter WC, Rush DR, Schneider P, Talbert RL.

Pharmacotherapy. 1993 May-Jun;13(3):262-6.

PMID:
8321740
42.

Stability of ondansetron hydrochloride injection in extemporaneously prepared oral solutions.

Graham CL, Dukes GE, Fox JL, Kao CF, Hak LJ.

Am J Hosp Pharm. 1993 Jan;50(1):106-8.

PMID:
8427264
43.

Influence of gastrointestinal site of drug delivery on the absorption characteristics of ranitidine.

Williams MF, Dukes GE, Heizer W, Han YH, Hermann DJ, Lampkin T, Hak LJ.

Pharm Res. 1992 Sep;9(9):1190-4.

PMID:
1409403
44.

Ranitidine does not alter adinazolam pharmacokinetics or pharmacodynamics.

Suttle AB, Songer SS, Dukes GE, Hak LJ, Koruda M, Fleishaker JC, Brouwer KL.

J Clin Psychopharmacol. 1992 Aug;12(4):282-7.

PMID:
1527233
45.

Stability of ondansetron in large-volume parenteral solutions.

Graham CL, Dukes GE, Kao CF, Bertch JM, Hak LJ.

Ann Pharmacother. 1992 Jun;26(6):768-71.

PMID:
1535245
46.

Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine.

Hermann DJ, Krol TF, Dukes GE, Hussey EK, Danis M, Han YH, Powell JR, Hak LJ.

J Clin Pharmacol. 1992 Feb;32(2):176-83.

PMID:
1613128
47.

Pharmacotherapy specialty certification examination. III. Results of initial administration. The Board of Pharmaceutical Specialties' Specialty Council on Pharmacotherapy.

Vlasses PH, Rush DR, Dukes GE, Gal P, Miller WA, Porter WC, Schneider P, Talbert RL, Zarowitz BJ.

Pharmacotherapy. 1992;12(6):491-4. No abstract available.

PMID:
1492015
48.

Pharmacotherapy specialty certification examination. II. Blueprint to examination. The Board of Pharmaceutical Specialties' Specialty Council on Pharmacotherapy.

Talbert RL, Gal P, Dukes GE, Miller WA, Porter WC, Rush DR, Schneider P, Vlasses PH, Zarowitz BJ.

Pharmacotherapy. 1992;12(6):484-90. No abstract available.

PMID:
1492014
49.

Pharmacotherapy specialty certification process. I. Role delineation study. The Board of Pharmaceutical Specialties' Specialty Council on Pharmacotherapy.

Dukes GE, Gal P, Miller WA, Porter WC, Rush DR, Schneider P, Talbert RL, Vlasses PH, Zarowitz BJ.

Pharmacotherapy. 1992;12(6):477-83. No abstract available.

PMID:
1492013
50.

Evaluation of the pharmacokinetic interaction between diazepam and ACC-9653 (a phenytoin prodrug) in healthy male volunteers.

Hussey EK, Dukes GE, Messenheimer JA, Brouwer KL, Donn KH, Krol TF, Hak LJ.

Pharm Res. 1990 Nov;7(11):1172-6.

PMID:
2293218

Supplemental Content

Loading ...
Support Center